IL243295A0 - Carbazole carboxamide compounds are useful as kinase inhibitors - Google Patents

Carbazole carboxamide compounds are useful as kinase inhibitors

Info

Publication number
IL243295A0
IL243295A0 IL243295A IL24329515A IL243295A0 IL 243295 A0 IL243295 A0 IL 243295A0 IL 243295 A IL243295 A IL 243295A IL 24329515 A IL24329515 A IL 24329515A IL 243295 A0 IL243295 A0 IL 243295A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
compounds useful
carboxamide compounds
carbazole carboxamide
carbazole
Prior art date
Application number
IL243295A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL243295A0 publication Critical patent/IL243295A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL243295A 2013-06-25 2015-12-22 Carbazole carboxamide compounds are useful as kinase inhibitors IL243295A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839130P 2013-06-25 2013-06-25
PCT/US2014/043980 WO2014210087A1 (en) 2013-06-25 2014-06-25 Carbazole carboxamide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL243295A0 true IL243295A0 (en) 2016-02-29

Family

ID=51210832

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243295A IL243295A0 (en) 2013-06-25 2015-12-22 Carbazole carboxamide compounds are useful as kinase inhibitors

Country Status (13)

Country Link
US (1) US9714234B2 (enExample)
EP (1) EP3013815B1 (enExample)
JP (1) JP6353530B2 (enExample)
KR (1) KR102345381B1 (enExample)
CN (1) CN105473573B (enExample)
AU (1) AU2014302550A1 (enExample)
BR (1) BR112015031432A2 (enExample)
CA (1) CA2916504A1 (enExample)
EA (1) EA025863B1 (enExample)
IL (1) IL243295A0 (enExample)
MX (1) MX2015016771A (enExample)
SG (1) SG11201510028PA (enExample)
WO (1) WO2014210087A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI676618B (zh) * 2014-10-24 2019-11-11 美商必治妥美雅史谷比公司 三環化合物
MX393057B (es) 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
CN105802100A (zh) * 2016-04-22 2016-07-27 宁波硫华聚合物有限公司 橡胶促进剂粘合剂六甲氧基甲基蜜胺预分散母胶粒及其制备方法
CN105694150A (zh) * 2016-04-25 2016-06-22 无锡智谷锐拓技术服务有限公司 一种耐油橡胶
CN105670057A (zh) * 2016-04-25 2016-06-15 无锡智谷锐拓技术服务有限公司 一种耐油橡胶的制备方法
CN105907150A (zh) * 2016-06-02 2016-08-31 扬州兰都塑料科技有限公司 一种电缆涂料用阻燃剂
CN106084903A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种电缆外部涂覆的水性防火涂料的制备方法
CN106045972B (zh) * 2016-06-03 2018-11-16 中山大学 咔唑-利凡斯的明二联体及其药物组合物和应用
EP4100408B1 (en) 2020-02-03 2024-02-28 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008519843A (ja) 2004-11-10 2008-06-12 シージーアイ ファーマスーティカル インコーポレーテッド 特定のイミダゾ[1,2−a]ビラジン−8−イラミンズ、その生成方法及びそれに関する使用方法
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1954290B1 (en) 2005-11-22 2012-07-25 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
CN101573348A (zh) 2006-09-11 2009-11-04 矩阵实验室有限公司 作为pde-4和pde-10的抑制剂的二苯并呋喃衍生物
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
EP2231143B1 (en) 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
EP2599763A1 (en) 2008-02-14 2013-06-05 Siemens Molecular Imaging, Inc. Novel imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2307418B1 (en) * 2008-07-18 2014-03-12 F.Hoffmann-La Roche Ag Novel phenylimidazopyrazines
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos

Also Published As

Publication number Publication date
BR112015031432A2 (pt) 2017-07-25
MX2015016771A (es) 2016-03-31
KR102345381B1 (ko) 2021-12-29
EA201690012A1 (ru) 2016-05-31
CA2916504A1 (en) 2014-12-31
JP6353530B2 (ja) 2018-07-04
EA025863B1 (ru) 2017-02-28
WO2014210087A1 (en) 2014-12-31
EP3013815A1 (en) 2016-05-04
AU2014302550A1 (en) 2016-02-11
US20160200710A1 (en) 2016-07-14
KR20160022890A (ko) 2016-03-02
SG11201510028PA (en) 2016-01-28
JP2016523908A (ja) 2016-08-12
CN105473573A (zh) 2016-04-06
CN105473573B (zh) 2018-03-16
EP3013815B1 (en) 2017-05-03
US9714234B2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
ME03740B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
IL256500B (en) Heterocyclic amides as kinase inhibitors
IL241165A0 (en) Bi-aryl amide compounds as kinase inhibitors
IL244224A0 (en) Pyro- and Thiane-Pyrimide Carboxamide Compounds for Use as Pim Kinase Inhibitors
SG11201510028PA (en) Carbazole carboxamide compounds useful as kinase inhibitors
IL243296B (en) Tetrahydrocarbazole and carbazole carboxamide compounds are useful as kinase inhibitors
PL2970235T3 (pl) Nowe inhibitory
PL3030561T3 (pl) N-cyjanometyloamidy jako inhibitory kinaz janusowych
GB201307155D0 (en) Kinase inhibitors
HK1224673A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors